We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · June 12, 2022

Ruxolitinib vs Best Available Therapy in Inadequately Controlled Polycythaemia Vera Without Splenomegaly

The Lancet Haematology

 

Additional Info

The Lancet Haematology
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
Lancet Haematol 2022 May 18;[EPub Ahead of Print], F Passamonti, F Palandri, G Saydam, J Callum, T Devos, P Guglielmelli, AM Vannucchi, E Zor, M Zuurman, G Gilotti, Y Zhang, M Griesshammer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading